(Tipiracil hydrochloride + trifluridine) is under clinical development by Taiho Oncology and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Cancer have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Tipiracil hydrochloride + trifluridine)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Tipiracil hydrochloride + trifluridine) overview
Tipiracil hydrochloride and Trifluridine (Orcantas, Lonsurf) is a fixed dose combination that acts as an anti-neoplastic agent, where tipiracil is an inhibitor of the FTD-degrading enzyme thymidine phosphorylase and trifluridine is an antineoplastic nucleoside analog. It is formulated as film coated tablets, coated tablets for oral route of administration. It is indicated for the treatment of unresectable advanced or recurrent colorectal cancer, gallbladder cancer, biliary tract cancer, high grade, extrapulmonary neuroendocrine carcinoma, esophageal cancer, including squamous cell carcinoma, adenoid squamous cell carcinoma (Pseudoglandular squamous cell carcinoma), basaloid squamous cell carcinoma. Lonsurf is indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy, for the treatment of adult patients with metastatic gastric cancer or adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior lines of chemotherapy including a fluoropyrimidine, a platinum, and either a taxane or irinotecan and if appropriate with HER2/neu-targeted therapy.
TAS-102 is under development for the treatment of colorectal cancer, rectal cancer, metastatic pancreatic neuroendocrine tumors (second line therapy), metastatic urothelial cacner, refractory metastatic colorectal cancer, gastrointestinal tumors, metastatic and locally advanced unresectable pancreatic adenocarcinoma, adenocarcinoma of the gastroesophageal junction and squamous cell non-small cell lung cancer. It was also under development for small cell lung cancer, pancreatic ductal adenocarcinoma.
Taiho Oncology overview
Taiho Oncology, a subsidiary of Taiho Pharmaceutical Co Ltd, is a provider of cancer treatments and solutions. The company manufactures and markets cancer anti-metabolites as well as targeted small molecule inhibitors. Its products portfolio includes oral drugs for the treatment of gastric cancer, colorectal cancer and a variety of solid tumors. Taiho Oncology’s pipeline products includes anti metabolic agents and selectively targeted agents. The company’s LONSURF is an anti cancer drug for the treatment of metastatic colorectal cancer. Taiho Oncology is headquartered in Princeton, New Jersey, the US.
For a complete picture of (Tipiracil hydrochloride + trifluridine)’s drug-specific PTSR and LoA scores, buy the report here.